Research programme: lysosome pathway modulators - Catabasis Pharmaceuticals

Drug Profile

Research programme: lysosome pathway modulators - Catabasis Pharmaceuticals

Alternative Names: CAT 5000

Latest Information Update: 07 May 2013

Price : $50

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders

Most Recent Events

  • 07 May 2013 Programme is still in early research in US
  • 01 May 2013 Preclinical trials in Metabolic disorders in USA (unspecified route)
  • 28 Sep 2011 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top